27.10
-0.35 (-1.26%)
AIStockmoo 评分
| 价值 30% | -0.8 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报低于资本成本。资本回报上升。 参考 | |
| 时机 30% | -2.0 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 3.5 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+16.17%的股份:199家增持,147家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化-7.1%,回补天数8.7天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向不一,评分因此减弱。 | |
| 不计入评分 | |
| 股价低于其52周平均水平。5年来上涨。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 支撑与阻力没有明确信号。 参考 | |
| 最终评分 | -0.13 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Cogent Biosciences, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| COGT | - | - | - | 11.00 |
| FOLD | 5 B | - | - | - |
| IGMS | 71 M | - | - | 0.760 |
| SLGL | - | - | - | 3.80 |
| ACAD | - | - | - | 2.34 |
| CYTK | - | - | - | - |
|
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.04% |
| 机构持股比例 | 103.39% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 30 Jun 2026 | 5,503,418 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 125.70%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 199 | 35,045,215 |
| 减持 | 147 | 17,227,854 |
| 新建仓 | 57 | 13,674,570 |
| 清仓 | 58 | 3,356,114 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 17,416,118 | 8.7 |
| 15 Oct 2026 | 19,661,566 | 8.9 |
| 30 Sep 2026 | 19,462,718 | 8.1 |
| 15 Sep 2026 | 18,126,492 | 11.8 |
| 31 Aug 2026 | 18,747,531 | 12.1 |
| 14 Aug 2026 | 18,411,111 | 8.9 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Nov 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Faces A Valuation Test As FDA Decisions Draw Closer
Cogent Biosciences (COGT) reported widening third quarter losses and a busy regulatory calendar, posting a net loss of US$111.43 million as it approaches several FDA decisions on bezuclastinib. Cogent Biosciences’ share price has come under pressure in recent months, with the stock down about 30%… |
| 05 Nov 2026 | Yahoo Finance |
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results
Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026NonAdvSM PDUFA target action date December 30, 2026; AdvSM PDUFA target action date June 29, 2027 Cash balance of $791.1 million expected to fund operations into late 2028 WALTHAM, Mass. and BOULDER, Colo.… |
| 27 Oct 2026 | Yahoo Finance |
Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
WALTHAM, Mass. and BOULDER, Colo., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in a fireside chat at the Guggenheim 3rd Annual… |
| 20 Oct 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Three Regulatory Reviews, No Established Earnings Base Cogent Biosciences, Inc. (NASDAQ:COGT) has moved from proving bezuclastinib’s clinical activity to seeking regulatory approvals across distinct diseases. Its immediate valuation depends on a series of FDA decisions, starting with the November… |
| 25 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA
Cogent Biosciences has delivered very strong share price gains over the past five years, so the obvious question for you now is whether that move is backed up by what sits on its balance sheet. After a powerful run and fresh regulatory progress, investors are increasingly asking how today’s… |
| 24 Sep 2026 | Yahoo Finance |
Cogent Biosciences (COGT) Looks Fully Valued Following FDA NDA Acceptance
Cogent Biosciences (COGT) just received U.S. Food and Drug Administration acceptance of its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, with no advisory committee planned and no review issues flagged. Despite the FDA momentum, Cogent Biosciences shares have eased… |
| 24 Sep 2026 | Yahoo Finance |
Will FDA’s Streamlined Bezuclastinib Review in ASM Change Cogent Biosciences’ (COGT) Narrative?
Cogent Biosciences recently announced that the FDA has accepted its New Drug Application for bezuclastinib in Advanced Systemic Mastocytosis, set a PDUFA action date of June 29, 2027, and indicated no current plans for an advisory committee or identified review issues. The filing builds on pivotal… |
| 15 Sep 2026 | Yahoo Finance |
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set for June 29, 2027 WALTHAM, Mass. and BOULDER, Colo., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Cogent… |
近期信号 K线形态与EMA交叉
AI 技术分析
投资组合